ERBB2 and breast carcinoma: Another drawback is (in comparison to luminal breast cancers) the smaller number of HER2-enriched and triple-negative cancers in our patient collective (Fig. 3); however, this reflects the normal distribution of molecular subtypes of breast cancer in a patient population.